ArticleEJHaem2026

Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort.

Zhen Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.